Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis

Tanghetti E, Stein Gold L, Lain E, Jacobson A. Clinical profile of halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with hyperkeratotic plaque psoriasis. J Drugs Dermatol. 2025;24(6):590-598. doi:10.36849/JDD.8720R1.

Authors

Emil Tanghetti (ORCID: https://orcid.org/0000-0002-1115-3219)
Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
Edward Lain (ORCID: https://orcid.org/0000-0002-0762-1251)
Abby Abby

Publication Details

Journal: Journal of Drugs in Dermatology
Published: 2025-05-01
DOI: https://doi.org/10.36849/jdd.8720
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis

Emil Tanghetti, Linda Stein Gold, Edward Lain, Abby Abby

May 1, 2025

Journal of Drugs in Dermatology

Psoriasis: Treatment and Pathogenesis

article

Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis

Emil Tanghetti, Linda Stein Gold, Edward Lain, Abby Abby

May 1, 2025article en

Abstract

Journal of Drugs in DermatologyVol. 24(6)

Openalex Percentile: Top 86%

Psoriasis: Treatment and Pathogenesis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis — Emil Tanghetti, Linda Stein Gold, et al. · Journal of Drugs in Dermatology (2025) | TGRS Research Map | TGRS